Patents by Inventor Ádám VANNAY

Ádám VANNAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Sigma-1 receptor agonist compounds
    Patent number: 10842794
    Abstract: Compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. Embodiments relate to the use of Sigma-1 receptor agonists for use in the treatment of prevention of progressive fibrosis characterized by the over proliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1 agonists are disclosed.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: November 24, 2020
    Assignees: Támogatott Kutatócsoportok Irodája, Semmelweis Egyetem, SigmaDrugs Kft.
    Inventors: Andrea Fekete, Ádám Vannay, Endre Illés Kovács
  • COMPOSITIONS FOR ORGAN PRESERVATION
    Publication number: 20190335745
    Abstract: The invention relates to the field of preserving the viability of organs or tissues to be transplanted into a recipient in need of such a transplantation. In particular, the invention relates to use of a sigma 1 receptor agonist compound in preservation solutions and preservation solutions comprising a sigma 1 receptor agonist compound.
    Type: Application
    Filed: November 24, 2017
    Publication date: November 7, 2019
    Inventors: Andrea FEKETE, Ádám VANNAY, Ádám HOSSZÚ
  • NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS
    Publication number: 20190209575
    Abstract: Compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. Embodiments relate to the use of Sigma-1 receptor agonists for use in the treatment of prevention of progressive fibrosis characterized by the over proliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1 agonists are disclosed.
    Type: Application
    Filed: March 21, 2019
    Publication date: July 11, 2019
    Inventors: Andrea Fekete, Ádám Vannay, Endre Illés Kovács
  • Use of Sigma-1 receptor agonist compounds
    Patent number: 10124006
    Abstract: The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention relate to the use of Sigma-1 receptor agonists for use in the treatment or prevention of progressive fibrosis characterized by the overproliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1-receptor agonists are disclosed.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: November 13, 2018
    Assignees: MTA Tämogatott Kutatócsoportok Irodája, Semmelweis Egyetem
    Inventors: Andrea Fekete, Ádám Vannay
  • NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS
    Publication number: 20160346290
    Abstract: The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention relate to the use of Sigma-1 receptor agonists for use in the treatment or prevention of progressive fibrosis characterized by the overproliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1-receptor agonists are disclosed.
    Type: Application
    Filed: February 9, 2015
    Publication date: December 1, 2016
    Inventors: Andrea FEKETE, Ádám VANNAY